About ESP
Our Vision
Excellence in pathology for optimal patient care.
Our Mission
As the leading force in European pathology, the European Society of Pathology (ESP) promotes high quality pathology diagnosis for all patients, up-to-date education across Europe and support cutting-edge research to understand disease and translate science into clinical practice.
The European Society of Pathology (ESP)
Established in 1963, has its headquarters in Brussels and represents the leading European force in Pathology with more than 5,000 active members, 25 Working Groups (WG) and affiliated Societies and 30 national pathology societies.
ESP provides on-site and on-line educational, training and scientific programmes as well as funding opportunities to ESP members.
The ESP organises the European Congress of Pathology (ECP), holds several virtual and on-site postgraduate courses each year, among others through the European School of Pathology, ESP Academy, Giordano Fellowship and others and has an official journal: “Virchows Archiv”.
The ESP interacts with national pathology societies in Europe and has a significant number of established collaborations with other European organisations, clinical and scientific associations, and international pathology societies.
All ESP educational and training programmes (e.g., Courses, ESP Academy, Giordano Fellowship) and scientific activities will inevitably advance pathology in Europe and greatly facilitate communication between European pathologists.
The ESP Foundation, established in 2016, provides educational and training programmes in different pathology areas as well as external quality assessment (EQA) programmes for several biomarkers. Diagnostic laboratories worldwide participate in the ESP Foundation QA schemes, such as Lung, Colon and PDL1.
Our Target Audiences
- Attending Pathologists (certified diagnostic and academic)
- Residents and pathologists in training
- Clinical scientists, biologists, bioinformaticians, molecular diagnosticians, technicians, etc.
- Patient organisations
- Industry (Diagnostics, Pharma and Technology firms)
- Potential audience might be all or part of the multidisciplinary tumour board (oncologists/pathologists/surgeons/radiologists/geneticists, pharmacists, nurses, etc.
